Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Oncology Pharma Inc. ONPH OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Oncology Pharma Inc. (ONPH) is a Biotechnology company in the Healthcare sector, currently trading at $0.07. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Net income is $5,820 (loss), growing at +46.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $0 equity. Total assets: $0.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Fail), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

ONPH SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 15/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ONPH

✗
VALUE Fail
15/100
ONPH trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
ONPH: +0%/yr revenue is, +46.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
100/100
Balance sheet ONPH: Debt-to-Equity (D/E) ratio N/A, Current ratio is N/A. Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ONPH: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.364
Volume7.88K
Avg Volume (30D)45.22K
Market Cap$1.92M
Beta (1Y)2.39
Share Statistics
EPS (TTM)0.00
Shares Outstanding$82.16M
IPO Date1994-10-31
CEOGeorge Malesek
Financial Highlights & Ratios
EBITDA$-5.82K
Net Income$-5.82K
Operating Income$-5.82K
Price / Earnings (P/E)700
Analyst Forecast
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS68235J2015

Price Chart

Track all markets on TradingView
ONPH
Oncology Pharma Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.36

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 ANTX
ANTX
AN2 Therapeutics, Inc.
$2.98
-1.00%
 AVTE
AVTE
Aerovate Therapeutics, Inc.
$2.68
+0.00%
 ACRV
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.64
+1.86%
 ACOGF
ACOGF
Alpha Cognition Inc.
$5.73
+0.00%
 ANEB
ANEB
Anebulo Pharmaceuticals, Inc.
$0.50
-0.04%
 LVCLF
LVCLF
Living Cell Technologies Limited
$0.01
+0.00%
 MRES
MRES
Institute of Biomedical Research Corp.
$0.00
-16.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message